<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096705</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-137</org_study_id>
    <nct_id>NCT02096705</nct_id>
  </id_info>
  <brief_title>Phase III Insulin Add-On Asia Regional Program - ST</brief_title>
  <official_title>A 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate Efficacy and Safety of Dapagliflozin Added to Therapy of Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine if after 24 weeks of oral daily administration, there will be a
      greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with
      Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2
      diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2014</start_date>
  <completion_date type="Actual">January 28, 2016</completion_date>
  <primary_completion_date type="Actual">January 28, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change in HbA1c From Baseline to Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <description>The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <description>The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Body Weight From Baseline to Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <description>Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <description>The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">477</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1: Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Dapagliflozin Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Group 1: Dapagliflozin</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Group 2: Dapagliflozin Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c
             ≥ 7.5% and ≤ 11.0% obtained at screening visit

          -  Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at
             least 8 weeks prior to enrollment

        Inclusion criteria for randomization:

        HbA1c ≥ 7.5 and ≤ 10.5% at Day -14

        Exclusion Criteria:

          -  Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of
             Enrollment

          -  History of diabetic ketoacidosis of hyperosmolar nonketotic coma

          -  Clinically diagnosed Type 1 diabetes mellitus

          -  Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV

          -  Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg
             and/or diastolic blood pressure (DBP) ≥ 110 mmHg

          -  History of unstable or rapidly progressing renal disease

          -  History of severe hepatobiliary disease

          -  Mallingancy within 5 years of the screening/enrollment visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Xi An</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <results_first_submitted>January 13, 2017</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>477 participants were enrolled; 313 entered lead-in period; 272 participants were randomized to a treatment group. Of the 205 participants not randomized to a treatment group: 190 No longer met study criteria, 11 withdrew consent, 2 were lost to follow-up, and 2 were removed for administrative reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject request to discontinue treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129">5 participants in this arm did not complete the treatment period and rejoined for follow-up</participants>
                <participants group_id="P2" count="139">5 participants in this arm did not complete the treatment period and rejoined for follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects not reporting status</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Randomized Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="8.91"/>
                    <measurement group_id="B2" value="56.5" spread="8.39"/>
                    <measurement group_id="B3" value="57.5" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change in HbA1c From Baseline to Week 24</title>
        <description>The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.</description>
        <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
        <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in HbA1c From Baseline to Week 24</title>
          <description>The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.</description>
          <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
          <units>percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.0707"/>
                    <measurement group_id="O2" value="-0.87" spread="0.0666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for Dapagliflozin vs. placebo</p_value_desc>
            <method>Longitudinal repeated measure analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0968</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
            <estimate_desc>Difference of Dapagliflozin from placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24</title>
        <description>The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).</description>
        <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
        <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24</title>
          <description>The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).</description>
          <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="3.3803"/>
                    <measurement group_id="O2" value="-30.62" spread="3.1314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Longitudinal repeated measure analysis</method>
            <method_desc>P-value for Dapagliflozin vs. placebo</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-30.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.6050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.76</ci_lower_limit>
            <ci_upper_limit>-21.61</ci_upper_limit>
            <estimate_desc>Difference of Dapagliflozin from placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Body Weight From Baseline to Week 24</title>
        <description>Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).</description>
        <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
        <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Body Weight From Baseline to Week 24</title>
          <description>Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).</description>
          <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.2224"/>
                    <measurement group_id="O2" value="-1.00" spread="0.2103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for Dapagliflozin vs. placebo</p_value_desc>
            <method>Longitudinal repeated measure analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.98</ci_lower_limit>
            <ci_upper_limit>-0.77</ci_upper_limit>
            <estimate_desc>Difference of Dapagliflozin from placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24</title>
        <description>The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).</description>
        <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
        <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24</title>
          <description>The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).</description>
          <population>All randomized participants with non-missing baseline and at least one post-baseline value</population>
          <units>International Units (IU)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.3723"/>
                    <measurement group_id="O2" value="-0.70" spread="0.3592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <p_value_desc>P-value for Dapagliflozin vs. placebo</p_value_desc>
            <method>Longitudinal repeated measure analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5171</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.45</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
            <estimate_desc>Difference of Dapagliflozin from placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 week treatment period + 30 days</time_frame>
      <desc>Includes serious adverse events with onset on or after the first date/time of double-blind treatment and on or prior to the last day of double blind treatment plus 30 days. Includes non-serious adverse events with onset on or after the first date/time of double-blind treatment and on or prior to the last day of double blind treatment plus 4 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL BRIDGING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>UVEITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>NEUROSYPHILIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>PERIARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ARACHNOID CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="139"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="139"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Maria Langkilde</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

